Search

This paper presents a method that utilizes graph theory and state modelling algorithms to perform automatic complexity analysis of the architecture of cyber-physical systems (CPS). It describes cyber physical systems risk assessment (CPSRA), a tool to provide automatic decision support for enhancing the overall resilience of CPS architectures often used in critical infrastructures. CPRSA is built to enhance industrial risk assessment and improve the resilience of CPS architecture against malicious attacks on the cyber domain that can affect industrial processes, which is critical in a distributed cyber environment. Such attacks often compromise execution states on physical components and lead to hazards or even disasters through plant malfunction. CPSRA is tested against a real-world testbed model of a large SCADA system that is infused with real-world CVE vulnerabilities in some of its components. The tool creates an isomorphic graph of the CPS process model and uses graph algorithms and network analytics on the model to test cyber-attacks and evaluate attack resilience aspects. The tool's output is then used to pinpoint high-complexity components in terms of influence on the overall CPS architecture and suggest mitigation points for security measure implementation while considering every potential subattack path and subliminal path on the model's attack graph. The paper complements standardized assessment reports and contributes to automatic architecture assessment for critical infrastructure environments and can be used as the basis to model dependencies and threat propagation in larger digital twins, a need outlined in major NIST publications concerning the security of industrial systems that was previously done manually, without automatic insight into state and vulnerability influences. [ABSTRACT FROM AUTHOR]

During the post-coronavirus disease (COVID-19) era, a primary question is whether booster vaccination is effective against severe COVID-19 and should be recommended, particularly to individuals at high risk for severe disease (i.e., the elderly or those with additional severe comorbidities). From December 2020 to February 2023, a cohort study was conducted to estimate IgG and IgA immunogenicity and the dynamics of booster mono- and bivalent COVID-19 mRNA vaccines in 260 individuals (male/female: 114/146, median age: 68 years, interquartile range (IQR) = 31) who initially received either mRNA (218) or adenovirus-vector-based vaccines (42). Participants were followed until the 90th day after the third booster dose. Our cohort study indicated a beneficial effect of booster vaccination on the magnitude of IgG and IgA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. We found that second and third booster doses were more protective than one against fatal disease (p = 0.031, OR 0.08). In conclusion, booster COVID-19 vaccination should be strongly recommended, especially to individuals at high risk for severe/fatal disease. [ABSTRACT FROM AUTHOR]

Purpose: This study aims to provide an overview of the regulatory framework for AML supervision of cryptoassets. Design/methodology/approach: A review of current legislative framework in the EU is presented in this paper. Findings: A comprehensive framework is required to ensure that the AML risk posed by cryptoassets is mitigated. Originality/value: This is an original article written for presentation at the Economic Crime Symposium in Cambridge (Jesus College). [ABSTRACT FROM AUTHOR]

The aim of the study was to compare mRNA vaccine BNT162b2 with adenovirus vector- based vaccines in terms of presence of adverse reactions, immunogenicity, and protection against COVID-19. A total of 270 individuals were enrolled, of which 135 were vaccinated with adenovirus vector-based vaccines and compared with 135 age- and sex-matched participants who received the BNT162b2 mRNA vaccine. Serum sampling was performed on all participants on days 21, 42, 90, and 180 following the first dose, to evaluate anti-spike IgG and IgA responses. Antibodies were quantified by chemiluminescent microplate and ELISA assays. We demonstrate that both mRNA and adenovirus vector-based vaccines caused mild side-effects and were effective in inducing adequate antibody responses against SARS-CoV-2, although BNT162b2 was superior concerning the intensity of antibody responses and protection against severe COVID-19. Moreover, we identify that IgG and IgA responses depended primarily on both history of previous COVID-19 infection and vaccination platform used, with individuals immunized with a single-dose vaccine having lower antibody titers over time. Lastly, all vaccine platforms had limited side-effects, with the most frequent pain at the injection site. Our results provide useful information regarding antibody responses after vaccination with different vaccine platforms, which can be useful for public health vaccination strategies. [ABSTRACT FROM AUTHOR]